Table of Content

1. Executive Summary
   1.1. Europe Personalized Medicine Biomarkers Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Europe Sectorial Outlook
       2.3.2. Europe GDP Growth Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Product Adoption Analysis
   3.2. Recent Product Approvals and Launches Insights
   3.3. Regulatory Landscape
   3.4. Value Chain Analysis
   3.5. PESTLE Analysis
   3.6. Porter’s Five Force Analysis
4. Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Mn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2022
       4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
   4.3. Europe Personalized Medicine Biomarkers Market Outlook: Application
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019 - 2022
       4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
           4.3.3.1. Diagnosis
           4.3.3.2. Monitoring
           4.3.3.3. Early Detection/Screening
           4.3.3.4. Treatment Selection
           4.3.3.5. Others
       4.3.4. Market Attractiveness Analysis: Application
   4.4. Europe Personalized Medicine Biomarkers Market Outlook: Indication
       4.4.1. Introduction / Key Findings
       4.4.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019 - 2022
       4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
           4.4.3.1. Oncology Diseases
           4.4.3.2. Autoimmune Diseases
           4.4.3.3. Cardiology
           4.4.3.4. Diabetes
           4.4.3.5. Neurology
           4.4.3.6. Others
       4.4.4. Market Attractiveness Analysis: Indication
5. Europe Personalized Medicine Biomarkers Market Outlook: Country
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Mn) Analysis, By Country, 2019 - 2022
   5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       5.3.1. Germany
       5.3.2. France
       5.3.3. U.K.
       5.3.4. Italy
       5.3.5. Spain
       5.3.6. Russia
       5.3.7. Rest of Europe
   5.4. Market Attractiveness Analysis: Country
6. Germany Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       6.2.1. By Application
       6.2.2. By Indication
   6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       6.3.1. Diagnosis
       6.3.2. Monitoring
       6.3.3. Early Detection/Screening
       6.3.4. Treatment Selection
       6.3.5. Others
   6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       6.4.1. Oncology Diseases
       6.4.2. Autoimmune Diseases
       6.4.3. Cardiology
       6.4.4. Diabetes
       6.4.5. Neurology
       6.4.6. Others
   6.5. Market Attractiveness Analysis
7. France Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       7.2.1. By Application
       7.2.2. By Indication
   7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       7.3.1. Diagnosis
       7.3.2. Monitoring
       7.3.3. Early Detection/Screening
       7.3.4. Treatment Selection
       7.3.5. Others
   7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       7.4.1. Oncology Diseases
       7.4.2. Autoimmune Diseases
       7.4.3. Cardiology
       7.4.4. Diabetes
       7.4.5. Neurology
       7.4.6. Others
   7.5. Market Attractiveness Analysis
8. UK Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   8.1. Key Highlights
   8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       8.2.1. By Application
       8.2.2. By Indication
   8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       8.3.1. Diagnosis
       8.3.2. Monitoring
       8.3.3. Early Detection/Screening
       8.3.4. Treatment Selection
       8.3.5. Others
   8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       8.4.1. Oncology Diseases
       8.4.2. Autoimmune Diseases
       8.4.3. Cardiology
       8.4.4. Diabetes
       8.4.5. Neurology
       8.4.6. Others
   8.5. Market Attractiveness Analysis
9. Italy Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       9.2.1. By Application
       9.2.2. By Indication
   9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       9.3.1. Diagnosis
       9.3.2. Monitoring
       9.3.3. Early Detection/Screening
       9.3.4. Treatment Selection
       9.3.5. Others
   9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       9.4.1. Oncology Diseases
       9.4.2. Autoimmune Diseases
       9.4.3. Cardiology
       9.4.4. Diabetes
       9.4.5. Neurology
       9.4.6. Others
   9.5. Market Attractiveness Analysis
10. Spain Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       10.2.1. By Application
       10.2.2. By Indication
   10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       10.3.1. Diagnosis
       10.3.2. Monitoring
       10.3.3. Early Detection/Screening
       10.3.4. Treatment Selection
       10.3.5. Others
   10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       10.4.1. Oncology Diseases
       10.4.2. Autoimmune Diseases
       10.4.3. Cardiology
       10.4.4. Diabetes
       10.4.5. Neurology
       10.4.6. Others
   10.5. Market Attractiveness Analysis
11. Russia Europe Personalized Medicine Biomarkers Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       11.2.1. By Application
       11.2.2. By Indication
   11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       11.3.1. Diagnosis
       11.3.2. Monitoring
       11.3.3. Early Detection/Screening
       11.3.4. Treatment Selection
       11.3.5. Others
   11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       11.4.1. Oncology Diseases
       11.4.2. Autoimmune Diseases
       11.4.3. Cardiology
       11.4.4. Diabetes
       11.4.5. Neurology
       11.4.6. Others
   11.5. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. Illumina, Inc.
           12.3.1.1. Overview
           12.3.1.2. Segments and Product
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. Laboratory Corporation of America Holding
       12.3.3. Quest Diagnostics Incorporated
       12.3.4. Agilent Technologies, Inc.
       12.3.5. Genome Medical, Inc.
       12.3.6. Coriell Life Sciences.
       12.3.7. Roche Diagnostics
       12.3.8. NeoGenomics Laboratories
       12.3.9. FOUNDATION MEDICINE, INC.
       12.3.10. Guardant Health
       12.3.11. PerkinElmer
       12.3.12. Bio-Rad Laboratories
       12.3.13. GE Healthcare
       12.3.14. Qiagen
       12.3.15. Thermo Fisher Scientific Inc.
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations